369OBiomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505). (25th November 2018) - Zhou, Q; Zhang, X-C; Tu, H-Y; Gan, B; Wang, B-C; Xu, C-R; Chen, H-J; Zheng, M-Y; Wang, Z; Bai, X-Y; Sun, Y-L; Myers, A; et al.